Neuroprotection in glaucoma
Glaucoma treatment is currently focused solely on lowering of intraocular pressure. We can do this effectively with eye drops, laser, or surgical treatments.
These have all been shown to effectively slow but not halt disease progression in most forms of glaucoma. Advancing age and genetic risk are additional major risk factors for glaucoma, but these currently lack effective therapies.
During this Live event, Professor Crowston will discuss the need for neuroprotection in glaucoma, address some of the challenges associated with developing new treatments and discuss some recent advances that are creating excitement within the field.
Topic: Neuroprotection in glaucoma - the need, the challenges and recent advances to developing new treatments for glaucoma
Date: Monday 29th September 2025
Time: 07:00 PM AEST
To watch this event on YouTube and participate in the discussion please register now.
✨ About the speaker ✨
Jonathan Crowston is an ophthalmologist and clinician-scientist, appointed Professor of Ophthalmology at Sydney University in November 2022, and glaucoma consultant at Royal Prince Alfred Hospital. Previously, he led the Centre for Vision Research at Duke-NUS Singapore and prior to that was the Ringland Anderson Professor of Ophthalmology and Director of the Centre for Eye Research Australia. Following ophthalmology training at Moorfields Eye Hospital in London, he completed glaucoma fellowships at the University of Sydney and UC San Diego and earned a PhD at University College London as a Wellcome Vision Fellow.
His research is both laboratory and clinical-based and focuses on glaucoma and related optic neuropathies. His team is investigating how advancing age and associated metabolic dysfunction increase optic nerve susceptibility to glaucoma. He was recently awarded a $50M grant from the Snow Medical Research Foundation (SMRF) to establish the Snow Vision Accelerator and develop novel treatments that protect the optic nerve in glaucoma.
He has authored over 230 publications and co-edited a major textbook in glaucoma. In total he has contributed to securing over $120M in competitive and philanthropic research grants, and founded two startups, Oculo and Vitradel. He serves as a scientific advisor to several other biotech and pharmaceutical companies. He has received a number of national and international awards for research, mentorship, and education.
